Scoopfeeds — Intelligent news, curated.
BMO upgrades Replimune stock rating on FDA filing progress
business

BMO upgrades Replimune stock rating on FDA filing progress

Investing.com · Jun 30, 2026, 8:50 AM

BMO upgrades Replimune stock rating on FDA filing progress

Read full story on Investing.com → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop